ReviewFrontiers in oncology2019
Herbal Interaction With Chemotherapeutic Drugs-A Focus on Clinically Significant Findings.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 5 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Physicians' Knowledge and Experiences of Counseling on Complementary, Alternative, and Integrative Medicine in Cancer Care: a Qualitative Systematic Review.Current oncology reports · 2026Pooled it
- Pooled it
- Drug-herb combination therapy in cancer management.Molecular biology reports · 2022Pooled it
- Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Efficacy of Herbal Medicines Intervention for Colorectal Cancer Patients With Chemotherapy-Induced Gastrointestinal Toxicity - a Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- From mycelium to medicine: fungal strategies in the fight against resistance, cancer, and viral infections-insights from egyptian studies.Folia microbiologica · 2026Review
- Review
- Plant-Derived Bioactive Compounds and Their Therapeutic Potential in Cancer.International journal of molecular sciences · 2026Review
- Exploring biologically-based complementary and alternative medicine use among Irish cancer survivors: findings from a national survey.The oncologist · 2026Article
- Subtherapeutic exposure in doxorubicin pharmacokinetics among Ugandan breast cancer patients: a pilot study with implications for personalized therapy.BMC research notes · 2026Article
- Review
- Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy.Nutrition & metabolism · 2026Review
- Article
- Complementary and Alternative Therapy Use Among Cancer Patients in Qassim: Patterns, Predictors, and Patient Perspectives.Cancer management and research · 2026Article
- "At least i am doing something": a health belief model-guided qualitative study of nutritional supplement use among cancer patients during treatment.Frontiers in nutrition · 2026Article
- Clinical, laboratory, and medication-related factors associated with in-hospital mortality among oncology patients at a tertiary hospital in Saudi Arabia.Frontiers in pharmacology · 2026Article
- Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility.Current medicinal chemistry · 2026Review
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
- Complementary therapies in early breast cancer: Oncologists' evidence-based decisions in a Southeast European vignette survey.Biomolecules & biomedicine · 2025Article
- Factors associated with herbal medicine use among patients with cancer attending a tertiary hospital in Southwestern Uganda: a cross-sectional study.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most consequential risks associated with the concomitant use of herbal products and chemotherapeutic agents is herb-drug interactions. The risk is higher in patients with chronic conditions taking multiple medications. Herb-drug interaction is particularly undesirable in cancer management because of the precipitous dose-effect relationship and toxicity of chemotherapeutic agents. The most common mechanism of herb-drug interaction is the herbal-mediated inhibition and/or induction of drug-metabolizing enzymes (DME) and/or transport proteins leading to the alteration in the pharmacokinetic disposition of the victim drug. Most mechanistic research has focused on laboratory-based studies, determining the effects of herbal products on DMEs and extrapolating findings to predict clinical relevance; however, not all DME/transporter protein inhibition/induction results in clinical herb-drug interaction. This study reviews relevant literature and identified six herbal products namely echinacea, garlic, ginseng, grapefruit juice, milk thistle, and St John's wort, which have shown interactions with chemotherapeutic agents in humans. This focus on clinically significant herb-drug interaction, should be of interest to the public including practitioners, researchers, and consumers of cancer chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.